{"id":2333,"date":"2017-09-22T16:56:11","date_gmt":"2017-09-22T11:26:11","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2333"},"modified":"2025-05-12T14:28:38","modified_gmt":"2025-05-12T08:58:38","slug":"isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics","title":{"rendered":"Isocitrate dehydrogenase (IDH) inhibitors\u2013 Emerging Anti-Cancer Therapeutics"},"content":{"rendered":"<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The enzyme, <strong>isocitrate dehydrogenase<\/strong> (IDH) catalyzes the oxidative decarboxylation of <strong>isocitrate<\/strong>, producing <strong>alpha-ketoglutarate<\/strong> and <strong>CO2<\/strong>. It is found in the cytosol, mitochondrial matrix, and peroxisomes. <strong>IDH<\/strong> is responsible for cellular respiration in the TCA cycle. Isocitrate dehydrogenase exists in three isoforms including <a href=\"https:\/\/www.delveinsight.com\/report-store\/isocitrate-dehydrogenase-idh1-inhibitor-pipeline-insight\"><strong>IDH1<\/strong><\/a> (<\/span>homodimeric<span style=\"color: #000000;\"><strong> enzyme<\/strong> which is primarily found in cytoplasm and peroxisomes), <strong>IDH2<\/strong> (also a homodimeric enzyme located within the mitochondria) and <strong>IDH3<\/strong> (a heterotetrameric enzyme found in the mitochondria).<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">Inhibitors of this enzyme are being developed as therapeutics targeting IDH mutation in cancers. Various studies conducted on these inhibitors have demonstrated that they are capable of binding to the alpha-ketoglutarate site and consequently act as binding competitors.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">There is only one marketed product <strong>Idhifa<\/strong>, developed by <strong>Celgene<\/strong> which got approved in August 2017 by the <strong>USFDA<\/strong>. It is indicated for the treatment of patients with relapsed or refractory acute myeloid leukemia with an IDH2 mutation. The sale of<strong> Idhifa<\/strong> is estimated to reach <strong>USD 465.44 million<\/strong> by <strong>2025<\/strong>.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">The pipeline of IDH inhibitors is at a nascent stage with only a handful of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/isocitrate-dehydrogenase-idh1-inhibitor-pipeline-insight\">IDH1<\/a><\/strong> and IDH2 inhibitors under development. <strong>Agios Pharmaceuticals<\/strong> has emerged as a key player in the market which is developing <strong>two<\/strong> products, one in <strong>Phase III<\/strong> (late-stage) and the other in <strong>Phase I<\/strong> (early stage). These inhibitors mainly target oncology based indications including <strong>acute myeloid leukemia, hematologic malignancies, glioma, and chondrosarcomas.<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #000000;\">There is a high unmet need for new therapies targeting this enzyme. Therefore, the promising therapeutic potential of mutant IDH inhibitors can pave the way for cancer treatment individualization to improve outcomes.<\/span><\/p>\n<p><strong><em>Ayushi Sinha<\/em><\/strong><\/p>\n<p><strong><em>Associate Analyst<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The enzyme, isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate and CO2. It is found in the cytosol, mitochondrial matrix, and peroxisomes. IDH is responsible for cellular respiration in the TCA cycle. Isocitrate dehydrogenase exists in three isoforms including IDH1 (homodimeric enzyme which is primarily found in cytoplasm and peroxisomes), IDH2 (also [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2335,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1054,1049,155,204,1047,1050,1051,1052,1053,1048,472,474],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-2333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-agios-pharmaceuticals","tag-alpha-ketoglutarate","tag-celgene","tag-delveinsight","tag-idh","tag-idh1","tag-idh2","tag-idh3","tag-idhifa","tag-isocitrate-dehydrogenase-inhibitors","tag-phase-i","tag-phase-iii","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Isocitrate dehydrogenase inhibitors Emerging Anti-Cancer Therapeutics<\/title>\n<meta name=\"description\" content=\"The enzyme, isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate and CO2....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Isocitrate dehydrogenase inhibitors Emerging Anti-Cancer Therapeutics\" \/>\n<meta property=\"og:description\" content=\"The enzyme, isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate and CO2....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-22T11:26:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T08:58:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"852\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Isocitrate dehydrogenase inhibitors Emerging Anti-Cancer Therapeutics","description":"The enzyme, isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate and CO2....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics","og_locale":"en_US","og_type":"article","og_title":"Isocitrate dehydrogenase inhibitors Emerging Anti-Cancer Therapeutics","og_description":"The enzyme, isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate and CO2....","og_url":"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-09-22T11:26:11+00:00","article_modified_time":"2025-05-12T08:58:38+00:00","og_image":[{"width":852,"height":480,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics","name":"Isocitrate dehydrogenase inhibitors Emerging Anti-Cancer Therapeutics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/1.jpg","datePublished":"2017-09-22T11:26:11+00:00","dateModified":"2025-05-12T08:58:38+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The enzyme, isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate and CO2....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/isocitrate-dehydrogenase-idh-inhibitors-emerging-anti-cancer-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/1.jpg","width":852,"height":480},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021346\/1-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Agios Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">alpha-ketoglutarate<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Celgene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IDH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IDH1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IDH2<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IDH3<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Idhifa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Isocitrate dehydrogenase inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase I<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Phase III<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Agios Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">alpha-ketoglutarate<\/span>","<span class=\"advgb-post-tax-term\">Celgene<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">IDH<\/span>","<span class=\"advgb-post-tax-term\">IDH1<\/span>","<span class=\"advgb-post-tax-term\">IDH2<\/span>","<span class=\"advgb-post-tax-term\">IDH3<\/span>","<span class=\"advgb-post-tax-term\">Idhifa<\/span>","<span class=\"advgb-post-tax-term\">Isocitrate dehydrogenase inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Phase I<\/span>","<span class=\"advgb-post-tax-term\">Phase III<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Sep 22, 2017","modified":"Updated on May 12, 2025"},"absolute_dates_time":{"created":"Posted on Sep 22, 2017 4:56 pm","modified":"Updated on May 12, 2025 2:28 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2333"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2333\/revisions"}],"predecessor-version":[{"id":32052,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2333\/revisions\/32052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2335"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2333"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2333"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}